glp 1 drugs kidney disease GLP-1 receptor agonists in patients with chronic and either overweight or obesity GLP-1 Use in Non-Diabetics Associated

Several macro and micro-level drivers are driving this obesity care revolution: Rising Prevalence : By 2030, nearly half the worlds population will be living with overweight or obesity, an alarming epidemiological trend that brings public health systems to a tipping point

Collaborations and pharma partnerships for obesity drug development are accelerating innovation, combining expertise to bring next-generation therapies to market faster

Although there are drawbacks to taking GLP-1 drugs (such as muscle loss), they are viewed as a miracle drug by many who have struggled for years with obesity

Int J Neurosci (2021) p:138

Understanding whether these effects are direct pharmacological actions or secondary to weight loss remains an important clinical question